Skip to main content
SpringerLink
Log in

The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of this study was the evaluation of clinical usage of metalloproteinase (MMP): proMMP-1, MMP-2, MMP-7, MMP-9, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in serum of patients with rectal cancer, as well as the selection of parameters of the greatest diagnostic sensitivity and the determination of their relation with clinicopathological features, what is more, the demonstration whether their concentrations may have a prognostic value in the assessment of disease-free survival (DFS) and overall survival (OS). The study comprised 100 patients with rectal cancer including 29 women and 71 men. The tested group was comprised of qualified patients without distant metastasis (M0). It was demonstrated that in patients with rectal cancer, the concentrations of MMP-9, MMP-7, and proMMP-1 as well as TIMP-1 were significantly higher in comparison to the reference group. On the basis of ROC curves, the greatest diagnostic sensitivity of MMP-9 was demonstrated. When evaluating the correlation of tested parameters with the size of the tumor (T1–T2 vs T3–T4), essential differences were shown for proMMP-1 concentrations. The highest percentage of patients with progression had an increased concentration of MMP-7 and TIMP-1. During a 5-year follow-up, univariate log-rank analysis had shown an essential dependence between the concentration of MMP-7 in men and DSF which was confirmed in Cox multivariate analysis. It was demonstrated that the pretreatment concentration of proMMP-1 may be clinically useful when evaluating the mass of the tumor, whereas MMP-7 may be a prognostic factor for DFS in men with rectal cancer without distant metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;6:1374–403.

    Article  Google Scholar 

  2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;12:2893–917.

    Article  Google Scholar 

  3. de Gramont A, de Gramont A, Chibaudel B, et al. GERCOR (French Oncology Research Group). From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol. 2011;4:521–32.

    Article  Google Scholar 

  4. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;4:511–20.

    Article  Google Scholar 

  5. Donada M, Bonin S, Barbazza R, et al. Management of stage II colon cancer—the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 2013;13:36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (RGTM) guidelines. Eur J Cancer. 2003;39:718–27.

    Article  CAS  PubMed  Google Scholar 

  7. Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokines measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor. Tumor Biol. 2005;26:186–94.

    Article  CAS  Google Scholar 

  8. Mroczko B, Groblewska M, Okulczyk B, et al. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis. 2010;25(10):1177–84.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.

    CAS  PubMed  Google Scholar 

  10. Said A, Raufman J, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers. 2014;6:366–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lukaszewicz-Zajac M, Mroczko B, Guzinska-Ustymowicz K, et al. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci. 2013;58:235–43.

    Article  CAS  PubMed  Google Scholar 

  12. Li C-Y, Yuan P, Lin S-S, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumor Biol. 2013;34:735–41.

    Article  CAS  Google Scholar 

  13. Polistena A, Cucina A, Dinicola S, et al. MMP7 expression in colorectal tumours of different stages. In vivo. 2014;28:105–10.

    CAS  PubMed  Google Scholar 

  14. Groblewska M, Mroczko B, Gryko M, et al. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumor Biol. 2014;35:3793–80.

    Article  CAS  Google Scholar 

  15. Rutkowski A, Zajac L, Pietrzak L, et al. Surgical site infections following short-term radiotherapy and total mesorectal excision: results of a randomized study examining the role of gentamicin collagen implant in rectal cancer surgery. Tech Coloproctol 2014, Jul 4. [Epub ahead of print]

  16. Nesteruk D, Rutkowski A, Fabisiewicz S, et al. Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data. Biomed Res Int. 2014;2014:712827.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Murray D, Morrin M, McDonnell S. Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res. 2004;24:489–94.

    CAS  PubMed  Google Scholar 

  18. Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer. 2007;97:971–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78–86.

    Article  CAS  PubMed  Google Scholar 

  20. Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004;98:173–7.

    Article  PubMed  Google Scholar 

  21. Oberg A, Hoythya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085–91.

    CAS  PubMed  Google Scholar 

  22. Ishida H, Murata N, Hayashi Y, et al. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today. 2003;33:885–92.

    Article  CAS  PubMed  Google Scholar 

  23. Holten-Andersen M, Christensen IJ, Nilbert M, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer survival. A validation study. Eur J Cancer. 2004;1:64–72.

    Article  Google Scholar 

  24. Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–23.

    Article  CAS  PubMed  Google Scholar 

  25. Shiozawa J, Ito M, Nakayama T, et al. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol. 2000;9:925–33.

    Article  Google Scholar 

  26. Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000;2:108–11.

    Article  Google Scholar 

  27. Bendardaf R, Buhmeida A, Ristamaki R, et al. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol. 2007;42:1473–8.

    Article  CAS  PubMed  Google Scholar 

  28. Langenskiöld M, Ivarsson ML, Holmdahl L, et al. Intestinal mucosal MMP-1—a prognostic factor in colon cancer. Scand J Gastroenterol. 2013;48:563–9.

    Article  PubMed  Google Scholar 

  29. Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase 7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004;64:665–71.

    Article  CAS  PubMed  Google Scholar 

  30. Xing XJ, Gu XH, Ma TF. Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis. Tumor Biol 2014; Jul 25[Epub ahead of print]

  31. Luo HZ, Zhou ZG, Yang L, et al. Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol. 2005;12:739–44.

    Article  Google Scholar 

  32. Pryczynicz A, Gryko M, Niewiarowska K, et al. Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer. Folia Histochem Cytobiol. 2013;51:206–12.

    Article  CAS  PubMed  Google Scholar 

  33. Martínez-Fernandez A, García-Albeniz X, Pineda E, et al. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol. 2009;16:1412–20.

    Article  PubMed  Google Scholar 

  34. Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121(5):1066–71.

    Article  CAS  PubMed  Google Scholar 

  35. Yukawa N, Yoshikawa T, Akaike M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology. 2007;72:205–20.8.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781, Warsaw, Poland

    Malgorzata Fuksiewicz, Beata Kotowicz & Maria Kowalska

  2. Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781, Warsaw, Poland

    Andrzej Rutkowski

Authors
  1. Malgorzata Fuksiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beata Kotowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrzej Rutkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Kowalska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malgorzata Fuksiewicz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fuksiewicz, M., Kotowicz, B., Rutkowski, A. et al. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis. Tumor Biol. 36, 3629–3635 (2015). https://doi.org/10.1007/s13277-014-3000-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-3000-z

Keywords

Search

Navigation